Table 1 Platelet trends, associated events and treatments given to our patient over 12 years
Year | Platelet count (thousand/mm3) | Treatment | Events |
|---|---|---|---|
2001 | 10 | Rho(D) + prednisone | Menorrhagia |
2002 | 19 to 160 | Splenectomy | Menorrhagia |
2003 | 30 to 150 | Rituximab (weekly Ă—4) + high dose prednisone | Â |
2004 | 15 to 40 | Danazol; rituximab (Ă—2) | Â |
2005 | 13 to 22 | Vincristine (weekly Ă—4) | Â |
2006 | 20 to 30 | Observation | Hysterectomy |
2007 | 10 to 12 | High pulse decadron; rituximabĂ—1; low dose cyclosporine 2.5mg/kg | Intracranial hemorrhage |
2008 | 4 to 6 | Intravenous immunoglobulin G; decadron; rituximab (weeklyĂ—4) | Ruptured ovarian cyst |
2009 | 5 to 14 | Eltrombopag 50mg to 75mg daily (Ă—3 months) | Â |
2010 | 9 to 12 | Observation | Â |
2011 | 6 to 15 | Observation | Â |
2012 | 4 to 10 | Intravenous immunoglobulin G + prednisone + platelet transfusion | Intracranial hemorrhage |
|  |  | Romiplostim 8μg/kg to 10μg/kg |  |
2013 | 12 | Intravenous immunoglobulin + prednisone + platelet transfusion | Intracranial hemorrhage |